Hi Bear - 

I think Don tends to be optimistic on his schedulign estimates. 

It may not be favorable to have patients on the drug for too short a time, as it may take some time to see statistically significant responses.  The proteomics analsys was encouraging about the time to response, but that may or may not reflect rapid reduction of MACE events.  Previous studies were short and MACE reduction was still apparently significant for rosuvastatin. I wonder if it may prove significant for atorvastatin too after all with more time. Dunno. 

But as to your feeling - if it is just that the time frame may be longer, I suspect you are right. Just my take.